Transcatheter aortic valve replacement use in young patients before and after the first low-risk trial publication
Transcatheter aortic valve replacement (TAVR) use in young patients has recently increased.1 The high-risk nature of TAVR explant and unknown long-term valve durability are important considerations of TAVR use among young patients with expected longevity.1 Although current US guidelines recommend surgical aortic valve replacement (SAVR) in low-risk patients younger than age 65 years,2 the first guideline specifying such age threshold was published after US Food and Drug Administration (FDA) approval of TAVR for low-risk patients during 2019.
Authors
- Makoto Mori (ORCID: https://orcid.org/0000-0002-2367-8354)
- Roland Assi (ORCID: https://orcid.org/0000-0002-0863-9867)
- Isaac George (ORCID: https://orcid.org/0000-0001-7770-4450)
- Luigi Pirelli (ORCID: https://orcid.org/0000-0001-7656-9293)
- Hiroo Takayama (ORCID: https://orcid.org/0000-0002-7840-801X)
- Arnar Geirsson (ORCID: https://orcid.org/0000-0002-8943-9962)
- Christina Waldron (ORCID: https://orcid.org/0000-0003-0286-6599)
Institutions
- Yale University (US)
- Columbia University (US)
Publication Details
- Journal
- JTCVS structural and endovascular.
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1016/j.xjse.2024.100033
- Citations
- 1
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.40